Aliskiren tablets bulk supplier for pharma manufacturers

Aliskiren Tablets 150 mg, 300 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 150 mg, 300 mg

Reference Brands: Tekturna(US & EU)

Aliskiren is a direct renin inhibitor that reduces the production of angiotensin I, lowering blood pressure. It decreases cardiovascular risk, improves hypertension control, and helps prevent stroke and heart failure. Benefits include blood pressure reduction, improved cardiovascular health, and enhanced long-term disease management with minimal side effects.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Aliskiren Tablets? List it or send an offer →

Product Description:

Aliskiren tablets, marketed as Tekturna, are approved in the US by the FDA and in the EU via EMA for hypertension management. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial and safety data, while the EMA ensures regional safety and manufacturing compliance. Proper adherence to regional regulations supports timely approval, safe use, and worldwide availability of aliskiren tablets, helping improve blood pressure control and reduce cardiovascular risks globally.

Aliskiren Tablets — third party manufacturing & bulk supply

Aliskiren Tablets 150 mg, 300 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Aliskiren Tablets is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Aliskiren Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Aliskiren Tablets →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Aliskiren is used to treat high blood pressure (hypertension) in adults. By lowering blood pressure, it helps reduce the risk of complications such as stroke, heart attack, and kidney problems. Aliskiren works by directly inhibiting renin, an enzyme involved in the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and fluid balance.

Aliskiren is made from the active pharmaceutical ingredient aliskiren hemifumarate, which is a direct renin inhibitor. It reduces the conversion of angiotensinogen to angiotensin I, thereby lowering downstream effects that increase blood pressure.

The main trade name is Tekturna. Other regional brand names include Rasilez and Valturna (in combination with valsartan).

The original brand Tekturna is marketed by Novartis. Other companies produce generic aliskiren formulations depending on regional approvals.

The generic name is aliskiren hemifumarate.

Brand names include Tekturna, Rasilez, and Valturna (combination with valsartan), along with regional generic versions.

Aliskiren is manufactured in regulated pharmaceutical facilities in the USA, EU, UK, India, and other countries depending on the manufacturer and marketing authorization holder.